Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
December 01 2022 - 08:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to develop and launch the first FDA-approved
ophthalmic formulation of bevacizumab for use in retinal
indications, today announced that Russ Trenary, President and Chief
Executive Officer of Outlook Therapeutics, will participate in a
panel discussion titled, “Take A Look At What's In Store For Wet
AMD & Related Diabetic Eye Diseases,” at the Cantor Fitzgerald
Medical & Aesthetic Dermatology, Ophthalmology & Medtech
Conference on Thursday, December 8, 2022 at 2:45 PM ET.
In addition to the panel presentation, management will be
available to participate in in-person one-on-one meetings with
qualified members of the investor community who are registered to
attend the conference.
The panel discussion is open to those who are registered to
attend the event. Please contact your Cantor representative for
more information.
About Outlook Therapeutics,
Inc.Outlook Therapeutics is a biopharmaceutical company
working to develop and launch ONS-5010/ LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab for use in retinal indications, including wet AMD,
DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission
for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29,
2023. The submission is supported by Outlook Therapeutics’ wet AMD
clinical program, which consists of three clinical trials: NORSE
ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab
is approved, Outlook Therapeutics expects to commercialize it as
the first and only FDA-approved ophthalmic formulation of
bevacizumab for use in treating retinal diseases in the United
States, United Kingdom, Europe, Japan, and other markets. For more
information, please visit www.outlooktherapeutics.com.
CONTACTS:Media Inquiries:Anna
ArmyAccount SupervisorLaVoie Health ScienceT:
617-351-0246aarmy@lavoiehealthscience.com
Investor Inquiries:Jenene ThomasChief Executive
OfficerJTC Team, LLCT: 833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Nov 2023 to Dec 2023
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Dec 2022 to Dec 2023
